Selective Estrogen Receptor Modulator Effects of Epimedium Extracts on Breast Cancer and Uterine Growth in Nude Mice

Abstract

Epimedium is popularly used in traditional Chinese medicine to treat sexual dysfunction, menstrual irregularity, and osteoporosis. The estrogenic effects of the prenylated flavonoids of Epimedium make it an attractive alternative for hormone replacement therapy. Here, we examined the therapeutic potential of the estrogenic herb extract of Epimedium brevicornum as an alternative to hormone replacement therapy in a breast cancer mouse model. To that end, athymic and ovariectomized female nude mice were subcutaneously injected into the mammary fat pads with MCF-7 breast cancer cells, randomly grouped and fed with soy-free feeds, alone or in combination with ethinyl estradiol or different doses of the estrogenic herb extract of E. brevicornum. Our findings demonstrate that unlike ethinyl estradiol, it did not promote the growth of breast cancer xenograft volume and weight, with the highest dose showing a significant reduction in growth and ERα protein content. Moreover, the extract increased uterine weight at the lowest dose, while higher doses had no effects. Put together, our data shows for the first time that despite the estrogenic activity of E. brevicornum, its action is largely tissue specific and dose-dependent. Our data on E. brevicornum presents in vivo evidence for its selective estrogen receptor modulator effect and warrants exploration of its use as an alternative to hormone replacement therapy in menopausal women.

Key words

Epimedium brevicornum - Berberidaceae - menopause - selective estrogen receptor regulator - breast cancer

^* These authors contributed equally to this work.

• References

• 1 Womenʼs Health Initiative (2010).. Available at http://www.nhlbi.nih.gov/whi/references.htm#ht Last updated on 21 September 2010.
• 2 Horst-Sikorska W, Wawrzyniak A. The role of hormonal therapy in osteoporosis. Endokrynol Pol 2011; 62: 61-64
• 3 McIntosh J, Blalock SJ. Effects of media coverage of Womenʼs Health Initiative study on attitudes and behavior of women receiving hormone replacement therapy. Am J Health Syst Pharm 2005; 62: 69-74
• 4 Ju YH, Doerge DR, Helferich WG. A dietary supplement for female sexual dysfunction, Avlimil, stimulates the growth of estrogen-dependent breast tumors (MCF-7) implanted in ovariectomized athymic nude mice. Food Chem Toxicol 2008; 46: 310-320
• 5 Low Dog T. Menopause: a review of botanical dietary supplements. Am J Med 2005; 118 (Suppl. 12) 98-108
• 6 Stearn WT. The genus Epimedium and other Herbaceous Berberidaceae. Portland: Timber Press, Incorporated; 2002
• 7 Li SZ. Ying Yang, Ben Cao Gang Mu. Beijing: Xue Yuan Publishing House; 1991
• 8 Abura A. Analysis of 133 cases of postmenopausal osteoporosis treatment. J XinJiang Med Univ 2006; 29: 548-549
• 9 Wang J, Hao X. Epimedium theoretical basis for the treatment of postmenopausal osteoporosis and pharmacological studies. Qindao Med J 2002; 34: 304-305
• 10 Zeng Y. Epimedium treatment of postmenopausal osteoporosis in 50 cases. ShanXi J Tradit Chin Med 2005; 26: 405-406
• 11 Zhao L. Epimedium clinical evaluation of osteoporosis prevention. Mod J Integr Tradit Chin Western Med 2003; 12: 922-923
• 12 Meng FH, Li YB, Xiong ZL, Jiang ZM, Li FM. Osteoblastic proliferative activity of Epimedium brevicornum Maxim. Phytomedicine 2005; 12: 189-193
• 13 Zhang CZ, Wang SX, Zhang Y, Chen JP, Liang XM. In vitro estrogenic activities of Chinese medicinal plants traditionally used for the management of menopausal symptoms. J Ethnopharmacol 2005; 98: 295-300
• 14 Zhang G, Qin L, Shi Y. Epimedium-derived phytoestrogen flavonoids exert beneficial effect on preventing bone loss in late postmenopausal women: a 24-month randomized, double-blind and placebo-controlled trial. J Bone Miner Res 2007; 22: 1072-1079
• 15 Ma H, He X, Yang Y, Li M, Hao D, Jia Z. The genus Epimedium: an ethnopharmacological and phytochemical review. J Ethnopharmacol 2011; 134: 519-541
• 16 Yong EL, Wong SP, Shen P, Gong YH, Li J, Hong Y. Standardization and evaluation of botanical mixtures: lessons from a traditional Chinese herb, Epimedium, with oestrogenic properties. Novartis Found Symp 2007; 282: 173-188 discussion 188–191
• 17 Yap SP, Shen P, Li J, Lee LS, Yong EL. Molecular and pharmacodynamic properties of estrogenic extracts from the traditional Chinese medicinal herb, Epimedium . J Ethnopharmacol 2007; 113: 218-224
• 18 Yap SP, Shen P, Butler MS, Gong Y, Loy CJ, Yong EL. New estrogenic prenylflavone from Epimedium brevicornum inhibits the growth of breast cancer cells. Planta Med 2005; 71: 114-119
• 19 Wong SP, Shen P, Lee L, Li J, Yong EL. Pharmacokinetics of prenylflavonoids and correlations with the dynamics of estrogen action in sera following ingestion of a standardized Epimedium extract. J Pharm Biomed Anal 2009; 50: 216-223
• 20 Li HB, Chen F. Separation and purification of epimedin A, B, C, and icariin from the medicinal herb Epimedium brevicornum maxim by dual-mode HSCCC. J Chromatogr Sci 2009; 47: 337-340
• 21 Yang L, Lu D, Guo J, Meng X, Zhang G, Wang F. Icariin from Epimedium brevicornum maxim promotes the biosynthesis of estrogen by aromatase (CYP19). J Ethnopharmacol 2013; 145: 715-721
• 22 Shen P, Guo BL, Gong Y, Hong DY, Hong Y, Yong EL. Taxonomic, genetic, chemical and estrogenic characteristics of Epimedium species. Phytochemistry 2007; 68: 1448-1458
• 23 Tiong CT, Chen C, Zhang SJ, Li J, Soshilov A, Denison MS, Lee LS, Tam VH, Wong SP, Xu HE, Yong EL. A novel prenylflavone restricts breast cancer cell growth through AhR-mediated destabilization of ERα protein. Carcinogenesis 2012; 33: 1089-1097
• 24 Allred CD, Allred KF, Ju YH, Virant SM, Helferich WG. Soy diets containing varying amounts of genistein stimulate growth of estrogen-dependent (MCF-7) tumors in a dose-dependent manner. Cancer Res 2001; 61: 5045-5050
• 25 Chu I, Arnaout A, Loiseau S, Sun J, Seth A, McMahon C, Chun K, Hennessy B, Mills GB, Nawaz Z, Slingerland JM. Src promotes estrogen-dependent estrogen receptor alpha proteolysis in human breast cancer. J Clin Invest 2007; 117: 2205-2215
• 26 Shao W, Keeton EK, McDonnell DP, Brown M. Coactivator AIB1 links estrogen receptor transcriptional activity and stability. Proc Natl Acad Sci U S A 2004; 101: 11599-11604
• 27 Ignar-Trowbridge DM, Teng CT, Ross KA, Parker MG, Korach KS, McLachlan JA. Peptide growth factors elicit estrogen receptor-dependent transcriptional activation of an estrogen-responsive element. Mol Endocrinol 1993; 7: 992-998
• 28 Bunone G, Briand PA, Miksicek RJ, Picard D. Activation of the unliganded estrogen receptor by EGF involves the MAP kinase pathway and direct phosphorylation. EMBO J 1996; 15: 2174-2183
• 29 Atanaskova N, Keshamouni VG, Krueger JS, Schwartz JA, Miller F, Reddy KB. MAP kinase/estrogen receptor cross-talk enhances estrogen-mediated signaling and tumor growth but does not confer tamoxifen resistance. Oncogene 2002; 21: 4000-4008
• 30 Xie F, Wu CF, Lai WP, Yang XJ, Cheung PY, Yao XS, Leung PC, Wong MS. The osteoprotective effect of Herba epimedii (HEP) extract in vivo and in vitro . Evid Based Complement Alternat Med 2005; 2: 353-361
• 31 Soule HD, Vazguez J, Long A, Albert S, Brennan M. A human cell line from a pleural effusion derived from a breast carcinoma. J Natl Cancer Inst 1973; 51: 1409-1416
• 32 Shen P, Wong SP, Li J, Yong EL. Simple and sensitive liquid chromatography-tandem mass spectrometry assay for simultaneous measurement of five Epimedium prenylflavonoids in rat sera. J Chromatogr B Analyt Technol Biomed Life Sci 2009; 877: 71-78